Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Oct:31:61-71.
doi: 10.1016/j.cytogfr.2016.08.002. Epub 2016 Aug 25.

The CXCL8-CXCR1/2 pathways in cancer

Affiliations
Review

The CXCL8-CXCR1/2 pathways in cancer

Qian Liu et al. Cytokine Growth Factor Rev. 2016 Oct.

Abstract

Persistent infection or chronic inflammation contributes significantly to tumourigenesis and tumour progression. C-X-C motif ligand 8 (CXCL8) is a chemokine that acts as an important multifunctional cytokine to modulate tumour proliferation, invasion and migration in an autocrine or paracrine manner. Studies have suggested that CXCL8 and its cognate receptors, C-X-C chemokine receptor 1 (CXCR1) and C-X-C chemokine receptor 2 (CXCR2), mediate the initiation and development of various cancers including breast cancer, prostate cancer, lung cancer, colorectal carcinoma and melanoma. CXCL8 also integrates with multiple intracellular signalling pathways to produce coordinated effects. Neovascularisation, which provides a basis for fostering tumour growth and metastasis, is now recognised as a critical function of CXCL8 in the tumour microenvironment. In this review, we summarize the biological functions and clinical significance of the CXCL8 signalling axis in cancer. We also propose that CXCL8 may be a potential therapeutic target for cancer treatment.

Keywords: Angiogenesis; CXCL8; CXCR1; CXCR2; Cancer; Metastasis.

PubMed Disclaimer

Conflict of interest statement

Competing financial interests: The authors declare no competing financial interests.

Figures

Fig. 1.
Fig. 1.
PyMOL Molecular Graphics System was used to present above structures. (A, B). Corresponding transmembrane regions within CXCR1 tertiary structure. Regions marked in different colours with arrows showed its seven transmembrane domains. Simulation of tertiary structure was constructed using PDB lefiof 2LNL produced by Park et al. [17]. (C, D). Corresponding transmembrane regions within CXCR2 tertiary structure. Regions marked in different colours with arrows showed its seven transmembrane domains. The amino acid sequence of CXCR2, NCBI RefSeq NP_0015481, were used to model CXCR2 tertiary structure in Swiss Model [155]. (E, F). Interaction model between CXCL8-dimer and CXCR1 N-terminal. Simulation of tertiary structure was constructed using PDB le of 1ILP produced by Skeltonfiet al. [16].
Fig. 2.
Fig. 2.
The diagram summarizing the major signalling pathways of CXCL8 in cancers. CXCL8 chemoattractant myeloid-derived suppressor cells (MDSCs) and tumour-associated neutrophils (TAN) to tumour microenvironment which are associated with immune suppression. At the celluar level, CXCL8 binds to G protein-coupled receptors (GPCRs), namely CXCR1 or CXCR2, leading to the activation of G protein. Heterotrimeric Ga and bg subunits stimulate the main effectors PLC and PI3K to induce phosphorylation of PKC and Akt, respectively. The two signalling pathways have been reported to activate respective transcription factors associated to survival, angiogenesis and migration of tumour cells. In addition, CXCL8 activates non-receptor tyrosine kinases (e.g., Src and FAK) and members of the RhoGTPase family, which promote cell proliferation, survival, motility and invasion. Activated Raf-1/MAP/Erk signalling cascade contributes to cell proliferation and survival. Dashed arrows, uncon rmed pathways involved in CXCL8 signalling axis.

Similar articles

Cited by

References

    1. Gulumian M, The role of oxidative stress in diseases caused by mineral dusts and fibres: current status and future of prophylaxis and treatment, Mol. Cell. Biochem 196 (1999) 69–77. - PubMed
    1. Balkwill F, Mantovani A, In ammation and cancer: back to Virchow, Lancet 357 (2001) 539–545. - PubMed
    1. Waugh DJ, Wilson C, The interleukin-8 pathway in cancer, Clin. Cancer Res 14 (2008) 6735–6741. - PubMed
    1. Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M, Multiple control of interleukin-8 gene expression, J. Leukoc. Biol 72 (2002) 847–855. - PubMed
    1. Brat DJ, Bellail AC, Van Meir EG, The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis, Neuro Oncol 7 (2005) 122–133. - PMC - PubMed

Publication types